The stock is in a pronounced downtrend, with a 1-year price change of -2.58% and a more severe 6-month decline of -41.59%, significantly underperforming the SPY's 30.59% gain over the same period. Currently trading at $52.12, the price sits near the lower end of its 52-week range ($41.73 to $104.32), indicating it is trading at approximately 10% above its 52-week low, which suggests the stock is deeply oversold but may also represent a falling knife scenario without a clear catalyst for reversal. Recent momentum shows a short-term bounce with a 1-month price change of +11.46%, sharply outperforming the SPY's +8.7% gain, indicating a potential oversold rally; however, the 3-month trend remains deeply negative at -20.21%, signaling the longer-term bearish pressure remains intact despite the recent rebound.

This recent positive 1-month momentum of +11.46% diverges from the prevailing 1-year downtrend, potentially signaling a technical relief rally or a bottoming attempt after the steep decline. The stock's relative strength versus the market is positive over one month (+2.76) but deeply negative over one year (-33.17), highlighting a stark short-term vs. long-term performance dichotomy. The price action from the data shows a sharp drop from highs above $90 in late October 2025 to lows near $42 in late March 2026, with the recent bounce to the $50-$56 range suggesting a consolidation phase.

Key technical levels are clearly defined, with immediate support at the 52-week low of $41.73 and major resistance at the 52-week high of $104.32. A sustained break below the $42 support could trigger further downside, while a move above the recent April high near $56.78 would be necessary to signal a more credible recovery attempt. With a short ratio of 5.82, the stock carries a high level of short interest, which could fuel a short-covering rally if positive catalysts emerge, but also indicates significant negative sentiment.

Tempus AI is exhibiting explosive revenue growth, with Q4 2025 revenue of $367.2 million representing an 82.98% year-over-year increase. This follows sequential quarterly growth from $255.7 million in Q1 2025, demonstrating strong momentum. The company's primary investment thesis is predicated on this rapid scaling of its platform, though the sustainability of this growth rate is a key question as the base expands. With no segment data available, the growth appears broad-based across its data and diagnostic offerings.

The company remains unprofitable on a net income basis, reporting a Q4 2025 net loss of $54.2 million, which improved from a loss of $79.98 million in Q3 2025. However, gross margins are exceptionally high and improving, reaching 89.74% in the latest quarter, up from 61.61% in Q3 2025, indicating a favorable shift toward higher-margin services or software. The operating margin was -13.13% in Q4, a significant improvement from -17.94% in Q3, suggesting operating leverage is beginning to materialize as revenue scales.

The balance sheet shows a debt-to-equity ratio of 1.66, indicating a leveraged capital structure, but a strong current ratio of 3.13 provides ample short-term liquidity. A major concern is cash flow: the trailing twelve-month free cash flow is deeply negative at -$404.0 million, and operating cash flow for the full year 2025 was -$218.1 million. The company's return on equity is deeply negative at -49.87%, reflecting significant losses relative to shareholder equity. The business is currently consuming cash to fund its growth, relying on its IPO proceeds and debt to finance operations.